| GNAQ mutations occur in about half of uveal melanomas, representing the most common known oncogenic mutation in this cancer. | skin, |
| Oncogenic mutations in GNAQ occur early in uveal melanoma. | skin, |
| The vast majority of primary large uveal melanomas harbor mutually-exclusive mutations in GNAQ or GNA11, but very rarely have the oncogenic mutations that are reported commonly in other cancers. | skin, |
| Letter/Case Report: oncogenic GNAQ mutation in congenital choroidal melanoma. | skin, |
| Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. | skin, |
| Oncogenic GNAQ mutation is associated with uveal melanoma. | skin, |
| Results found that GNAQ was highly expressed in gastric cancer (GC) patient samples and suggest that GNAQ plays a critical role in regulating GC cell growth and survival via canonical oncogenic signaling pathways including MAPK and p53. | gastric, |
| GNAQ oncogenic signaling induced YPA nuclear translocation and YAP-dependent transcription activation throuch Rho-GTPases and actin remodeling. | None |
| GNAQ/11 mutant clones make up a fraction of the cells in choroidal nevi. Nevus cells are furthermore characterised by heterogeneous YAP expression. Combined GNAQ/11 and YAP may constitute a putative precursor tumour pathway with an activated oncogene (GNAQ/11) and downstream effector (YAP). | None |